bTMB marker, detection kit and application bTMB marker

A technology of markers and reagents, applied in the field of medical molecular biology, can solve problems such as the inability to predict the effect of PDL1 immunotherapy
CN111424084AInactive Publication Date: 2020-07-17GENESEEQ TECH INC +1
3 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
GENESEEQ TECH INC
Publication Date
2020-07-17
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a blood tumor mutation burden (bTMB) marker, a detection kit and an application the bTMB marker, and belongs to the technical field of medical molecular biology. The inventionverifies clinical practicability of panel estimated bTMB as a biomarker, and the bTMB can be used for identifying patients responding to immunotherapy. On the other hand, research finds that circulating tumor DNA (ctDNA) MSAF is a new biomarker for predicting the therapeutic effect of immunotherapy. Importantly, low ctDNA release is significantly correlated with progression free survival (PFS) benefits, and comprehensive analysis of MSAF and bTMB can greatly enhance enrichment of potential responders. The research result is based on the liquid biopsy of blood, and the ctDNA has important clinical significance and practicability as a source of molecular markers of cancer immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a bTMB marker, a detection kit and its use, and belongs to the technical field of medical molecular biology. Background technique

[0002] Immune checkpoint inhibitors have revolutionized the treatment landscape for many advanced cancers [1]. However, only unselected patients can benefit long-term from immunotherapy [2,3]. Therefore, considerable efforts have been made to improve the efficacy of immunotherapy, including its combination with other anticancer therapeutic agents [4,5], and the identification of biomarkers predictive of efficacy [6-9]. For advanced non-small cell lung cancer (NSCLC), multiple biomarkers have been found to predict the clinical efficacy of PD-(L)1 mAb therapy [2,6,8,10-16], including high tumor mutational burden (TMB), reflecting the overall neoantigen load

[13] . However, most current studies are based on tissue samples, which may not be sufficient for multiple testing in advanced patients. Liq...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More